article thumbnail

Biden proposes subsidizing drug middlemen for insulin

World of DTC Marketing

The House is preparing to vote on a $35 monthly insulin cap later, but there is stern opposition to the plan, which could cost billions over ten years. Even with health insurance, some people pay up to $1,000 a month for insulin. Insulin Costs

Insulin 203
article thumbnail

Insulin prices demonstrate pharma’s greed

World of DTC Marketing

WHAT’S HAPPENING: In the Build Back Better bill , Democrats are actually proposing limiting insulin prices to $35 a month but Republicans can’t have any of that. PhRMA spent pharma’s money well and bought some politicians while people who need insulin are suffering.

Insulin 166
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

California files suit against PBMs over insulin prices

Bio Pharma Dive

The state filed suit Thursday against pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx, alleging they worked with drugmakers to drive up the price of insulin

Insulin 138
article thumbnail

Civica targets insulin in effort to produce cheaper drugs

Bio Pharma Dive

The nonprofit group announced ambitious plans to begin offering insulin at prices no higher than $30 per vial by early 2024

Insulin 241
article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin.

Insulin 262
article thumbnail

California to manufacture its own insulin, governor says

Bio Pharma Dive

Gavin Newsom announced a $100 million budget to create a production facility and to develop affordable insulin products, saying the medicines’ high cost “epitomizes market failures

Insulin 203
article thumbnail

FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar

Bio Pharma Dive

Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus

Insulin 231
article thumbnail

Positive results from trial of Arecor’s insulin candidate AT247

Pharma Times

Therapy demonstrates significantly accelerated insulin absorption and early exposure

Insulin 120
article thumbnail

Novo Nordisk once-weekly insulin clears first phase 3 test

Pharma Phorum

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. cases of hypoglycaemia per year with insulin icodec, versus 0.27

Insulin 83
article thumbnail

Why the drug pricing debate is focused on insulin

Pharma Phorum

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. Insulin rationing.

Insulin 104
article thumbnail

Fraudulent Eli Lilly Twitter Account Announces Free Insulin

XTalks

In Lilly’s case, the fake account claimed the company was giving out free insulin. A fraudulent Eli Lilly account with the username @EliLillyandCo tweeted a message on November 10 that said: “We are excited to announce insulin is free now.”.

Insulin 82
article thumbnail

Twitter trolls, Musk’s changes tank stocks for Lilly, other insulin makers

Pharma Phorum

In addition to the financial hit, the stunt has only served to draw attention to Lilly’s role in the insulin pricing crisis in the United States, where multiple patients have died because of rationing unaffordable insulin. That’s why other insulin stocks are falling too.

Insulin 82
article thumbnail

Insulin costs ignore the root cause of diabetes

World of DTC Marketing

President Biden is set to address the cost of insulin but what about the costs of obesity which are in the billions? The post Insulin costs ignore the root cause of diabetes. OPENING: As the NY Times recently reported , obesity is the leading cause of mortality in the United States.

Insulin 197
article thumbnail

Novo Nordisk submitting once-weekly insulin to FDA following Phase III success

Pharmaceutical Technology

Novo Nordisk has recently completed its six-part ONWARDS Phase III trial, as ONWARDS 5 reached its primary endpoint with Icodec demonstrating non-inferiority in reducing hemoglobin A1C (HbA1c) in patients with type 2 diabetes (T2D) at week 52 in comparison to once-daily basal insulin analogs.

Insulin 164
article thumbnail

Dopamine regulates insulin secretion through a complex of receptors, finds new study

Scienmag

Diabetes is a lifelong, chronic health condition caused by abnormalities in the body’s production and use of the hormone insulin. Research has shown that the feel-good hormone, dopamine (DA), plays a key role in how the body regulates the production of insulin.

Insulin 65
article thumbnail

Automated insulin dosing app Tidepool Loop FDA-cleared

Pharma Phorum

It is also the first application to enable insulin delivery from a compatible Apple Watch. Image source: Tidepool.org The post Automated insulin dosing app Tidepool Loop FDA-cleared appeared first on.

Insulin 56
article thumbnail

Endocrine Society applauds House for taking action to address insulin affordability

Scienmag

WASHINGTON—The Endocrine Society applauds the House of Representatives for hearing our call to improve insulin affordability for people with diabetes as it prepares to vote on the Affordable Insulin Now Act this week.

Insulin 70
article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

The SGLT-2I space is rapidly gaining market share from the DPP-4Is and other non-insulin anti-diabetic therapies as a barrage of clinical data in the last several years has demonstrated that they address the comorbidities of T2D.

Insulin 130
article thumbnail

Study finds disparities in access to insulin pumps among youth with type 1 diabetes

Scienmag

Latest News access among Diabetes disparities finds insulin pumps study type youth

Insulin 66
article thumbnail

Marine snail inspires fast-acting injectable insulin for better diabetes control

Scienmag

For millions of people with diabetes, insulin is essential medicine. But for some ocean-dwelling predators, insulin is a weapon. Chemistry AND Physics control Diabetes fastacting injectable inspires insulin Marine snail

Insulin 72
article thumbnail

Phase 3 trial dashes Oramed’s oral insulin hopes

Pharma Phorum

Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.

Insulin 56
article thumbnail

Novo Nordisk achieve headline results with icodec insulin

Pharma Phorum

Danish company Novo Nordisk have announced positive results from the ONWARDS 5 phase 3 trial, with once-weekly insulin icodec demonstrating superior reduction of HbA1 in people with type 2 diabetes, in combination with a dosing guide app.

Insulin 56
article thumbnail

Oramed hits oral insulin clinical trial milestone

BioPharma Reporter

Oramed Pharmaceuticals announced this week that it has enrolled 100% of the patients in the worldâs first Phase 3 study of oral insulin under FDA approved protocols.

Insulin 103
article thumbnail

Salk researchers find a new route for regulating blood sugar levels independent of insulin

Scienmag

LA JOLLA—(January 4, 2022) The discovery of insulin 100 years ago opened a door that would lead to life and hope for millions of people with diabetes. Biology blood find independent insulin levels regulating researchers route Salk sugar

Insulin 68
article thumbnail

Novo Scores Phase III Insulin Win, Potentially Strengthening Market Position

BioSpace

The results showed that insulin icodec is as non-inferior to Sanofi’s insulin glargine, Lantus, potentially bringing another major competitor into the insulin space

Insulin 70
article thumbnail

Oramed inks deal to commercialize oral insulin in South Korea

BioPharma Reporter

Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.

article thumbnail

Medtronic Expands Two Insulin Pump Recalls, Including One Over Cybersecurity Concerns

XTalks

Medtronic has expanded a Class I recall of remote controllers used with the MiniMed 508 insulin pump or the MiniMed Paradigm family of insulin pumps over potential cybersecurity risks.

Insulin 103
article thumbnail

Insulin glargine meets primary endpoint in Sanofi’s type 1 diabetes study

Pharma Times

InRange is the first worldwide multicentre RCT to compare second generation basal insulins

Insulin 104
article thumbnail

Lilly wades deeper into copycat insulin market, scoring interchangeability tag for Lantus biosim

Fierce Pharma

Lilly wades deeper into copycat insulin market, scoring interchangeability tag for Lantus biosim. fkansteiner. Fri, 11/18/2022 - 11:01

Insulin 83
article thumbnail

Exercise may protect brain volume by keeping insulin and BMI levels low

Scienmag

ET, WEDNESDAY, APRIL 13, 2022 Exercise May Protect Brain Volume by Keeping Insulin and BMI Levels Low MINNEAPOLIS – Studies have shown that exercise helps protect brain cells. A new study looking at the mechanisms involved in this relationship suggests that the role exercise plays in maintaining insulin and […]. Latest News BMI brain Exercise insulin Keeping levels protect VolumeEMBARGOED FOR RELEASE UNTIL 4 P.M.

Insulin 50
article thumbnail

House Passes Bill to Limit Cost of Insulin to $35 a Month

NY Times

Diabetes Law and Legislation Drugs (Pharmaceuticals) Insulin Prices (Fares, Fees and Rates) United States Politics and Government Democratic Party House of Representatives Senate Biden, Joseph R Jr

Insulin 83
article thumbnail

Hormone infusion improves pancreatic insulin production in cystic fibrosis patients with or at risk for diabetes

Scienmag

Latest News Cystic Diabetes fibrosis hormone improves infusion insulin pancreatic Patients production riskCystic fibrosis is well-known for attacking the lungs through thick blockages of mucus, but those with the condition often also develop diabetes because of the way cystic fibrosis can affect the pancreas. Since diabetes has been linked to worse lung function, this creates a vicious cycle, with diabetes acting as a multiplier on the patient’s […].

article thumbnail

Black and white US women have gut microbiome differences, and these may be associated with insulin resistance, a risk factor for diabetes

Scienmag

Biology Black Diabetes differences factor gut insulin microbiome resistance risk white women

Insulin 66
article thumbnail

Novo Nordisk launches first smart insulin pens for NHS patients

Pharma Phorum

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time. Smart insulin pens are expected to drive the insulin pen market from $13.8

Insulin 52
article thumbnail

Insulin producers face fresh lawsuit in US over pricing

Pharma Phorum

Arkansas has become the latest US state to issue a legal challenge to the big three insulin producers – Eli Lilly, Sanofi and Novo Nordisk – accusing them of deceptively driving up the price of the medicines. Today we begin the fight to stop this outrageous inflation of insulin pricing.”

Insulin 56
article thumbnail

Lilly wagers up to $1B on a biotech's plan for a new type of insulin

Bio Pharma Dive

Rival Novo Nordisk has jumped ahead in developing an injectable drug that responds to changes in blood sugar. An acquisition of Protomer Therapeutics could help Lilly close the gap

Insulin 236
article thumbnail

Lilly grabs glucose-sensing insulin tech, buying Protomer in $1bn deal

Pharma Phorum

Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the programme since then – it has just agreed to buy the company outright. .

Insulin 83
article thumbnail

Insulin price caps on the horizon as Senate leader plans vote

Pharma Phorum

The US Senate will vote in the coming weeks on whether to introduce a $35 cap on the monthly cost of insulin to patients that was endorsed by President Joe Biden in his 2022 State of the Union address. Some companies are already taking steps to provide lower-cost insulin.

Insulin 67
article thumbnail

With Congress weighing insulin cost cap, Sanofi slashes price for uninsured in US

Fierce Pharma

With Congress weighing insulin cost cap, Sanofi slashes price for uninsured in US. kdunleavy. Wed, 06/29/2022 - 11:28

Insulin 87
article thumbnail

Civica to Manufacture and Distribute Affordable Insulin

BioTech 365

Insulin 52
article thumbnail

Researchers overcome translational gap by developing novel in vivo model for the labeling of insulin secretory granule pools

Scienmag

Pancreatic beta cells produce, store and secrete insulin upon elevated blood glucose levels. However, the highly regulated process of insulin secretion, especially its molecular features and the stimuli behind this process have not yet been fully understood.

Insulin 52
article thumbnail

Changing the Narrative: Four Companies Working to Make Insulin More Accessible

BioSpace

million Americans who have diabetes, insulin has become increasingly expensive. Here are four organizations dedicated to making insulin more accessible For the 37.3

Insulin 71
article thumbnail

Once-weekly insulin icodec demonstrates superior reduction in HbA1c vs insulin degludec in people with type 2 diabetes in ONWARDS 2 phase 3a trial

The Pharma Data

Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec in 526 people with type 2 diabetes switching from daily insulin.

Insulin 52